Salubris Biotherapeutics Presents Updated Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Society for Clinical Oncology by jonadmin | May 30, 2026 | Uncategorized
Salubris Biotherapeutics Announces Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Conference by jonadmin | Apr 17, 2026 | Uncategorized
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress by jonadmin | Oct 18, 2025 | Uncategorized
ESMO 2025 Poster Presentation: A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), in Patients with Unresectable Locally Advanced or Metastatic Cancer by jonadmin | Oct 13, 2025 | Uncategorized
Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs by jonadmin | Sep 30, 2025 | Uncategorized
ASCO Trial in Progress Poster Presentation: A Phase 1/2 Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer by jonadmin | May 19, 2025 | Uncategorized
Recent Comments